What is ai-CANCERCH™ test?
The ai-CANCERCH™ test is a simple early cancer screening test that analyzes tumor-derived DNA floating in the bloodstream to predict the risk of six ongoing cancers.
*This test is unrelated to disease diagnosis, so consultation with a physician is essential for diagnosis and treatment planning.
The ai- CANCERCH™ test is recommended for individuals who:
• Want to know the presence of the six major cancers throughout the body without concerns about radiation exposure.
• Seek new screening tests rather than repetitive screening routines.
• Are looking for genetic tests to predict not only the onset of diseases in the future but also the presence of current cancers.
The principle of the ai-CANCERCH™
The test lies in liquid biopsy, which enables the detection of six types of cancer throughout the body with just one blood draw.
Liquid biopsy is a method of disease screening using bodily fluids such as blood.
In blood, various biomarkers that can be used for disease screening are present, among which cell-free DNA (cfDNA) stands out. cfDNA, released from cells into the bloodstream, carries the genetic characteristics of its originating cells. Therefore, cfDNA derived from cancer cells contains genetic information characteristic of cancer cells.
However, in the case of early-stage cancer, cfDNA derived from cancer cells exists in extremely small amounts in the bloodstream, making its extraction and analysis technically challenging and requiring advanced technology.
The ai-CANCERCH™ test analyzes various features of cancer cell DNA and integrates the results to screen for early-stage cancer through blood samples.
